Does the media prefer CLDX or FDMT?

In the previous week, Celldex Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Celldex Therapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Celldex Therapeutics' score of 0.78 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or QURE?

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for uniQure. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat uniQure's score of 0.85 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or BEAM?

In the previous week, Beam Therapeutics had 22 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 26 mentions for Beam Therapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Beam Therapeutics' score of 0.48 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMNM or FDMT?

In the previous week, Immunome had 7 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 11 mentions for Immunome and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Immunome's score of 1.08 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 5 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to FDMT or NAMS?

In the previous week, NewAmsterdam Pharma had 14 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat NewAmsterdam Pharma's score of 0.44 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 4D Molecular Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

4D Molecular Therapeutics (FDMT) Competitors

$13.17 -0.32 (-2.37%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.17 0.00 (0.00%)

As of 09/11/2026 07:56 PM Eastern

Compare

FDMT vs. CLDX, QURE, BEAM, IMNM, and NAMS

Should you buy 4D Molecular Therapeutics stock or one of its competitors? 4D Molecular Therapeutics's main competitors and comparable companies include Celldex Therapeutics (CLDX), uniQure (QURE), Beam Therapeutics (BEAM), Immunome (IMNM), and NewAmsterdam Pharma (NAMS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does 4D Molecular Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Celldex Therapeutics presently has a consensus price target of $56.42, suggesting a potential upside of 52.89%. 4D Molecular Therapeutics has a consensus price target of $29.63, suggesting a potential upside of 124.94%. Given 4D Molecular Therapeutics' higher possible upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Celldex Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the broader market.

4D Molecular Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,881.66	-$258.76M	-$4.35	N/A
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A

In the previous week, Celldex Therapeutics had 1 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 5 mentions for Celldex Therapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Celldex Therapeutics' score of 0.78 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celldex Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

Summary

4D Molecular Therapeutics beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to uniQure?

4D Molecular Therapeutics (NASDAQ:FDMT) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

4D Molecular Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, uniQure has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 3 mentions for uniQure. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat uniQure's score of 0.85 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4D Molecular Therapeutics has a net margin of -194.74% compared to uniQure's net margin of -1,350.73%. 4D Molecular Therapeutics' return on equity of -41.33% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
uniQure	-1,350.73%	-111.96%	-29.01%

4D Molecular Therapeutics currently has a consensus price target of $29.63, suggesting a potential upside of 124.94%. uniQure has a consensus price target of $65.00, suggesting a potential upside of 46.03%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

4D Molecular Therapeutics has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A
uniQure	$16.10M	191.78	-$198.97M	-$4.01	N/A

Summary

4D Molecular Therapeutics beats uniQure on 14 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Beam Therapeutics?

4D Molecular Therapeutics (NASDAQ:FDMT) and Beam Therapeutics (NASDAQ:BEAM) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are held by institutional investors. 7.9% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 22 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 26 mentions for Beam Therapeutics and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Beam Therapeutics' score of 0.48 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4D Molecular Therapeutics currently has a consensus price target of $29.63, suggesting a potential upside of 124.94%. Beam Therapeutics has a consensus price target of $49.00, suggesting a potential upside of 104.25%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe 4D Molecular Therapeutics is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

4D Molecular Therapeutics has a beta of 2.74, suggesting that its share price is 174% more volatile than the broader market. Comparatively, Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market.

Beam Therapeutics has a net margin of -54.75% compared to 4D Molecular Therapeutics' net margin of -194.74%. Beam Therapeutics' return on equity of -30.71% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
Beam Therapeutics	-54.75%	-30.71%	-24.07%

Beam Therapeutics has higher revenue and earnings than 4D Molecular Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A
Beam Therapeutics	$139.74M	17.73	-$79.99M	-$0.86	N/A

Summary

Beam Therapeutics beats 4D Molecular Therapeutics on 10 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to Immunome?

Immunome (NASDAQ:IMNM) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Immunome had 7 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 11 mentions for Immunome and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat Immunome's score of 1.08 indicating that 4D Molecular Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunome	5 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunome has a beta of 2.13, meaning that its stock price is 113% more volatile than the broader market. Comparatively, 4D Molecular Therapeutics has a beta of 2.74, meaning that its stock price is 174% more volatile than the broader market.

Immunome has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -194.74%. 4D Molecular Therapeutics' return on equity of -41.33% beat Immunome's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunome	N/A	-50.56%	-46.93%
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%

44.6% of Immunome shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 7.2% of Immunome shares are owned by insiders. Comparatively, 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunome presently has a consensus price target of $34.64, suggesting a potential upside of 40.40%. 4D Molecular Therapeutics has a consensus price target of $29.63, suggesting a potential upside of 124.94%. Given 4D Molecular Therapeutics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

4D Molecular Therapeutics has higher revenue and earnings than Immunome. Immunome is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunome	$6.94M	403.75	-$212.39M	-$2.53	N/A
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A

Summary

4D Molecular Therapeutics beats Immunome on 11 of the 17 factors compared between the two stocks.

How does 4D Molecular Therapeutics compare to NewAmsterdam Pharma?

4D Molecular Therapeutics (NASDAQ:FDMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 7.9% of 4D Molecular Therapeutics shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

4D Molecular Therapeutics currently has a consensus target price of $29.63, indicating a potential upside of 124.94%. NewAmsterdam Pharma has a consensus target price of $49.73, indicating a potential upside of 118.10%. Given 4D Molecular Therapeutics' higher possible upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
4D Molecular Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

4D Molecular Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D Molecular Therapeutics	$85.21M	8.54	-$140.11M	-$2.63	N/A
NewAmsterdam Pharma	$22.50M	121.13	-$203.82M	-$2.16	N/A

In the previous week, NewAmsterdam Pharma had 14 more articles in the media than 4D Molecular Therapeutics. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 4 mentions for 4D Molecular Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 1.35 beat NewAmsterdam Pharma's score of 0.44 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
4D Molecular Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	6 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

4D Molecular Therapeutics has a net margin of -194.74% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat 4D Molecular Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D Molecular Therapeutics	-194.74%	-41.33%	-35.90%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

4D Molecular Therapeutics has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Summary

4D Molecular Therapeutics and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FDMT vs. The Competition

Export

Metric	4D Molecular Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$727.56M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-5.01	14.18	274.94	25.27
Price / Sales	8.54	1,374.95	633.23	90.48
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	1.49	15.12	10.33	6.20
Net Income	-$140.11M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-12.02%	-4.34%	-3.32%	-2.35%
1 Month Performance	10.95%	-0.02%	-0.41%	-2.77%
1 Year Performance	93.39%	40.64%	19.21%	7.63%

4D Molecular Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FDMT 4D Molecular Therapeutics	3.7368 of 5 stars	$13.17 -2.4%	$29.63 +124.9%	+86.3%	$727.56M	$85.21M	N/A	120	Positive News
CLDX Celldex Therapeutics	1.9017 of 5 stars	$39.68 flat	$56.08 +41.3%	+46.4%	$3.12B	$1.54M	N/A	150	News Coverage Positive News Analyst Forecast
QURE uniQure	3.5328 of 5 stars	$44.50 flat	$65.00 +46.1%	+162.8%	$3.09B	$16.10M	N/A	500
BEAM Beam Therapeutics	2.338 of 5 stars	$29.66 flat	$49.00 +65.2%	+11.3%	$3.06B	$139.74M	N/A	510	Trending News Analyst Forecast Options Volume
IMNM Immunome	3.1076 of 5 stars	$26.76 flat	$34.64 +29.4%	+154.9%	$3.04B	$6.94M	N/A	40	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FDMT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. CLDX, QURE, BEAM, IMNM, and NAMS

How does 4D Molecular Therapeutics compare to Celldex Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to uniQure?

Summary

How does 4D Molecular Therapeutics compare to Beam Therapeutics?

Summary

How does 4D Molecular Therapeutics compare to Immunome?

Summary

How does 4D Molecular Therapeutics compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

4D Molecular Therapeutics (FDMT) Competitors

FDMT vs. CLDX, QURE, BEAM, IMNM, and NAMS

How does 4D Molecular Therapeutics compare to Celldex Therapeutics?

Do institutionals and insiders hold more shares of CLDX or FDMT?

Do analysts rate CLDX or FDMT?

Which has more volatility & risk, CLDX or FDMT?

Which has better valuation & earnings, CLDX or FDMT?

Does the media prefer CLDX or FDMT?

Is CLDX or FDMT more profitable?

Summary

How does 4D Molecular Therapeutics compare to uniQure?

Which has more volatility and risk, FDMT or QURE?

Do insiders & institutionals believe in FDMT or QURE?

Does the media refer more to FDMT or QURE?

Is FDMT or QURE more profitable?

Do analysts rate FDMT or QURE?

Which has better earnings & valuation, FDMT or QURE?

Summary

How does 4D Molecular Therapeutics compare to Beam Therapeutics?

Do institutionals & insiders hold more shares of FDMT or BEAM?

Does the media refer more to FDMT or BEAM?

Do analysts prefer FDMT or BEAM?

Which has more risk & volatility, FDMT or BEAM?

Is FDMT or BEAM more profitable?

Which has higher earnings & valuation, FDMT or BEAM?

Summary

How does 4D Molecular Therapeutics compare to Immunome?

Does the media prefer IMNM or FDMT?

Which has more risk & volatility, IMNM or FDMT?

Is IMNM or FDMT more profitable?

Do insiders & institutionals have more ownership in IMNM or FDMT?

Do analysts rate IMNM or FDMT?

Which has stronger valuation & earnings, IMNM or FDMT?

Summary

How does 4D Molecular Therapeutics compare to NewAmsterdam Pharma?

Do insiders and institutionals have more ownership in FDMT or NAMS?

Do analysts prefer FDMT or NAMS?

Which has stronger valuation and earnings, FDMT or NAMS?

Does the media refer more to FDMT or NAMS?

Is FDMT or NAMS more profitable?

Which has more volatility and risk, FDMT or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FDMT vs. The Competition

4D Molecular Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools